Company / Capital Expenditures
Integra Lifesciences Holdings Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$81.4M
FY2025
5-year range
$42.3M / $104.4M
FY2021-FY2025
Trend
-22.0%
vs FY2024
Sector context
#69 of 151
Health Care
What the data says
At $81M, Integra Lifesciences Holdings's capital expenditures ranks #69 of 151 in the Health Care sector. Capital Expenditures has fluctuated over the past 10 years, ranging from $33M in FY2017 to $104M in FY2024.
Based on SEC 10-K filings.
$81M in FY2025 with a 5-year CAGR of +15.9%.
Improved from $67M to $81M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +24.4%
- 5-Year CAGR
- +15.9%
- 10-Year CAGR
- -
Sector benchmark
#69 of 151 in Health CareTop 46% of 151This company $81.4M Sector average $271.7M
▼
-70.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +15.9%, indicating consistent growth.
- In FY2025, capital expenditures decreased 22.0% year-over-year.
- Ranks #69 out of 151 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $81.4M | -22.0% |
| FY2024 | $104.4M | +56.2% |
| FY2023 | $66.9M | +57.9% |
| FY2022 | $42.3M | -11.8% |
| FY2021 | $48.0M | +23.5% |
| FY2020 | $38.9M | -44.1% |
| FY2019 | $69.5M | -10.6% |
| FY2018 | $77.7M | +132.7% |
| FY2017 | $33.4M | -12.9% |
| FY2016 | $38.3M | +14.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026